Nanologica Taps Ardena CEO for Board as Syntagon Deal Deepens Ties

Nanologica AB ( (SE:NICA) ) has issued an update.

Nanologica AB, a Swedish life science tools provider, focuses on advanced purification consumables for peptide drugs like insulin and GLP-1 analogues, helping pharmaceutical manufacturers improve productivity and reduce costs in a niche market expanding with global diabetes and obesity drug demand. The company’s mission is to enhance access to cost-effective, life-saving treatments by extending the performance and durability of its chromatography products, and it is listed on Nasdaq Stockholm’s Main Market.

Nanologica’s main owner, Flerie Invest AB, has proposed Ardena Group CEO Jeremie Trochu as a new board member in connection with Nanologica’s acquisition of Ardena Södertälje, now renamed Syntagon. The nomination, to be decided at an extraordinary general meeting on March 4, is intended to cement ongoing collaboration with Ardena on joint customer projects and service needs, leveraging Trochu’s extensive CDMO and life science experience to support Nanologica’s strategic development.

Trochu brings 20 years of global experience in building and transforming life science and CDMO businesses, including a key role in Catalent’s evolution from private equity spin-off to listed global CDMO. His expertise in small and large molecule development, analytics, and M&A integration is expected to strengthen Nanologica’s board and support the integration and growth of Syntagon within the group.

Nanologica’s chair, Gisela Sitbon, highlighted that Trochu’s willingness to join the board underscores Ardena’s continued interest in Syntagon and the broader partnership. For stakeholders, the move signals a push to deepen commercial collaboration, enhance CDMO-facing capabilities, and potentially accelerate Nanologica’s growth trajectory by aligning its purification technologies more closely with the needs of large outsourcing partners.

The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK0.40 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.

More about Nanologica AB

Nanologica AB is a Swedish life science tools company that develops, manufactures, and sells advanced chromatographic consumables to pharmaceutical manufacturers. Its products are tailored for purification of peptide drugs such as insulin and GLP-1 analogues, aiming to boost productivity and cut costs in a growing global niche market driven by rising diabetes and obesity treatments.

By extending the lifetime and efficiency of purification media, Nanologica seeks to increase access to cost-effective medicines and broaden availability of life-saving therapies worldwide. Headquartered in Södertälje, the company is listed on Nasdaq Stockholm’s Main Market under the ticker NICA, serving pharma clients that require high-performance purification solutions at scale.

Average Trading Volume: 207,512

Technical Sentiment Signal: Sell

Current Market Cap: SEK36.05M

See more insights into NICA stock on TipRanks’ Stock Analysis page.